Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:37:55 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



V:NGEN - Nervgen Pharma Corp. - http://www.nervgen.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NGEN - V  0.72.20·2.231.72.23+0.2311.5244.35026742.05  2.24  1.983.98  1.5015:59:59Apr 1715 min RT 2¢
TSX-V - V0.72.20·2.231.72.23+0.2311.5155.43213452.05  2.24  1.983.98  1.5015:59:5915 min
NEO ATS - U 2.21+0.2110.517.235662.01  2.22  2.0115:58:2215 min
Alpha - A 2.21+0.2110.520.041562.02  2.23  2.0215:59:4415 min
Omega - O 2.21+0.2110.52.45112.01  2.23  2.0115:58:2215 min
Pure - P 2.19+0.199.53.98192.06  2.22  2.0615:57:4715 min
Chi-X - X 2.23+0.2311.512.426492.04  2.23  2.0115:59:5915 min
CX2 - H 2.22+0.2211.024.551652.02  2.24  2.0115:59:2915 min
CXD - D 2.12+0.126.00.92112.04  2.12  2.0412:52:5715 min
TriAct - M 2.007.61552    Sep 04-2015 min

Recent Trades - Last 10 of 674
Time ETExPriceChangeVolumeBuyerSellerMarkers
15:59:59X2.230.2310079 CIBC79 CIBCK
15:59:59X2.230.2310079 CIBC79 CIBCK
15:59:59V2.230.2340079 CIBC1 AnonymousK
15:59:59V2.230.2330079 CIBC1 AnonymousK
15:59:58V2.200.2020084 ITG841 AnonymousK
15:59:55V2.200.2010084 ITG841 AnonymousK
15:59:53V2.200.2010079 CIBC1 AnonymousK
15:59:48M2.230.231080 National Bank80 National BankE
15:59:48M2.220.2210080 National Bank1 Anonymous
15:59:44A2.210.2110079 CIBC1 AnonymousK

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2024-04-17 14:20C:NGEN2.02News ReleaseNervgen Pharma's Dec. 31 cash at $11.7-million
2024-04-03 20:43C:NGEN2.34Prospectus ApprovedNervgen Pharma prospectus offering
2024-03-28 13:21C:NGEN2.18News ReleaseNervgen Pharma closes $23.01-million bought deal
2024-03-22 07:38C:NGEN2.49Resume TradingNervgen Pharma resuming at the open
2024-03-21 16:12C:NGEN2.49News ReleaseNervgen Pharma arranges $20-million offering
2024-03-21 15:51C:NGEN2.55Halt TradingNervgen Pharma halted at 12:43 p.m. PT
2024-02-20 17:47C:NGEN3.32News ReleaseNervgen grants options to buy shares
2024-02-15 13:06C:NGEN3.01News ReleaseNervgen to complete NVG-291 enrolment in Q2 2024
2023-11-09 14:25C:NGEN1.96News ReleaseNervgen Pharma's Sept. 30 cash at $14.8-million
2023-11-09 10:12C:NGEN1.96SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-11-09 10:12C:NGEN1.96SEDAR Interim MD & ASEDAR Interim MD & A
2023-10-23 11:30C:NGEN1.79News ReleaseNervgen receives fast-track designation for NVG-291
2023-10-17 13:01C:NGEN1.75News ReleaseNervgen appoints Ruffolo as director
2023-09-25 09:56C:NGEN2.05News ReleaseNervgen doses first patient in spinal cord injury trial
2023-08-09 15:25C:NGEN1.85News ReleaseNervgen cash and investments at $16.1M at June 30
2023-08-09 08:28C:NGEN1.85SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-08-08 11:44C:NGEN1.85News ReleaseNervgen receives IRB OK for NVG-291 trial
2023-06-27 11:11C:NGEN1.71News ReleaseNervgen receives $3.18M (U.S.) grant for NVG-291 trial
2023-06-02 18:20C:NGEN1.70News ReleaseNervgen Pharma extends option expiry by two years
2023-05-23 17:34C:NGEN1.65News ReleaseNervgen grants options to buy 400,000 shares